Cardiac biomarkers in acute coronary syndromes: A review

Current Vascular Pharmacology

Volumn 8, Issue 3, 2010, Pages 388-393

  Amodio, Gianfranco ^a   Antonelli, Gianfranco ^a   Serio, Francesca Di ^a  

^a POLICLINICO   (Italy)

Author keywords

Acute coronary syndromes; Cardiac markers; Natriuretic peptide; Point of care; Troponin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MB; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; AMYLOIDOSIS; BLOOD SAMPLING; CANCER THERAPY; CARDIAC BIOMARKER; CARDIOTOXICITY; CONCENTRATION (PARAMETERS); CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; CRITICALLY ILL PATIENT; DISEASE MARKER; DYSPNEA; EARLY DIAGNOSIS; EARLY INTERVENTION; ECG ABNORMALITY; FIBRINOLYTIC THERAPY; GLYCOGEN STORAGE DISEASE TYPE 2; HALF LIFE TIME; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART INJURY; HEART SURGERY; HEART TRANSPLANTATION; HEMOGLOBINOPATHY; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; IMMUNOASSAY; KIDNEY FAILURE; LUNG EMBOLISM; MATERNAL HYPERTENSION; MYOCARDITIS; PERCUTANEOUS CORONARY INTERVENTION; PERICARDITIS; POINT OF CARE TESTING; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATIC FEVER; SEPSIS; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN;

ACUTE CORONARY SYNDROME; ANIMALS; BIOLOGICAL MARKERS; HUMANS; NATRIURETIC PEPTIDE, BRAIN; TROPONIN;

EID: 77952922472     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110791112250     Document Type: Review

References (61)

1. Anderson JL, Adams CD, Antman EM, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2007; 50:e1-e157.
2. The task force for the diagnosis and treatment of Non ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of Non ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-660.
3. Mega JL, Morrow DA, de Lemos JA. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE TIME 23 substudy. J Am Coll Cardiol 2004; 44: 335-39.
4. Jernberg T, Stridsberg M, Venge P, Lindhal B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2004; 40: 437-45.
5. Inoue M, Hori M, Nishimoto Y, et al. Immunological determination of serum m-AST activity in patients with acute myocardial infarction. Br Heart J 1978; 40: 1251-56.
6. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization. Task force on standardization of clinical nomenclature. Circulation 1979; 59: 607-8.
7. Adams JE 3rd, Abendeschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation 1993; 88: 750-63.
8. Jaffe AS, Ravkilde J, Roberts R. It's time for a change to a troponin standard. Circulation 1997; 95: 2053-9.
9. Jaffe AS, Babuin L, Apple FS. Biomarker in acute cardiac disease - The present and the future. J Am Coll Cardiol 2006; 48: 1-11.
10. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of Myocardial Infarction. Eur Heart J 2000; 21: 1502-13.
11. Alpert J, Thygesen K, for The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of Myocardial Infarction. J Am Coll Cardiol 2000; 36: 959-69.
12. Panteghini M. Acute coronary syndrome. Biochemical strategies in the troponin era. Chest 2002; 122: 1248-35.
13. Kokkunen H, Pentilla K, Kemppainen A. Differences in the diagnosis of myocardial infarction by troponin T compared with clinical and epidemiologic criteria. Am J Cardiol 2001; 88: 727-31.
14. Apple FS, Johari V, Hoybook KJ. Operationalizing cardiac troponine testing along ESC/ACC consensus guidelines for defining myocardial infarction: increasing rate of detection. Clin Chim Acta 2003; 331: 165-6.
15. Kontos MC, Fritz LM, Anderson FP, Tatum JL, Ornato JP, Jesse RL. Impact of the troponine standard in the prevalence of acute myocardial infarction. Am Heart J 2003; 146: 446-52.
16. Aviles RJ, Wright RS, Aviles JM. Long-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin I levels. Am J Cardiol 2002; 90: 875-78.
17. Rao SV, Ohman EM, Granger CB, et al. Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. Am J Cardiol 2003; 91: 936-40.
18. Ottani F, Galvani M, Nicolini FA. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000; 140: 917-27.
19. Lindhal B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000; 343: 1139-147.
20. James S, Armstrong P, Califf R. Troponin T levels and risk of 30- day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO IV trial. Am J Med 2003; 115: 178-84.
21. DeFilippi CR, Tocchi M, Parmar RJ. Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes: angiographic correlates and long-term clinical outcomes. J Am Coll Cardiol 2000; 35: 1287-34.
22. Hillis JS, Taggart P, Hillis L, Zhao N, Dalsey WC, Mangione A. Biochemical and clinical predictors of long-term outcome in patients with non-specific chest pain and nondiagnostic electrocardiograms. Am Heart J 2003; 145: 88-94.
23. Galvani M, Panteghini M, Ottani F. The new definition of myocardial infarction: analysis of the ESC/ACC criteria and reflection on its applicability to the Italian Health System. Ital Heart J 2002; 3: 543-57.
24. Newby KL, Roe MT, Chen AY, et al. Frequency and clinical implication of discordant Creatine Kinase-MB and troponin measurement in acute coronary syndromes. J Am Coll Cardiol 2006; 47: 312-18.
25. James SK, Lindhal B, Armstrong P. A rapid troponin I assay is not optimal for determination of troponine status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. Int J Cardiol 2004; 93: 113-20.
26. Panteghini M, Pagani F, Yeo KT. Evaluation of imprecision for cardiac troponin assay at low-range concentration. Clin Chem 2004; 50: 327-32.
27. Panteghini, M, Gerhardt W, Apple FS, Dati F, Ravkilde J, Wu AH. Quality specification for cardiac troponine assays, Clin Chem Lab Med 2001; 39: 175-79.
28. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J 2007; 28: 2525-538.
29. Frank JK, White HD. Clinical implication of the new definition of myocardial infarction. Heart 2004; 90: 99-106.
30. Blich M, Sebbag A, Attias J, Aronson D, Markiewicz W. Cardiac troponin I elevation in hospitalized patients without acute coronary syndromes. Am J Cardiol 2008; 101: 1384-8.
31. Dierks DB, Peacock FW, Hiestand BD, et al. Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in Non-ST-segment elevation Acute Coronary Syndromes (from the CRUSADE initiative). Am J Cardiol 2006; 97: 437-42.
32. Van de Verfe F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force of management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28-66.
33. Amodio G, Antonelli G, Varraso L, Ruggieri V, Di Serio F. Clinical impact of the troponin 99th percentile cut-off and clinical utility of myoglobin measurement in the early management of chest pain patients admitted to Emergency Cardiology Department. Coron Artery Dis 2007; 18: 181-86.
34. Macrae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem 2006; 52: 812-8.
35. Ilva T, Eriksson S, Lund J, et al. Improved early risk stratification and diagnosis of myocardial infarction, using a novel troponin I assay concept. Eur J Clin Invest 2005; 35: 112-6.
36. Eggers KM, Oldgren J, Nordenskjold A, Lindhal B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 2004; 148: 574-81.
37. Panteghini M. The new definition of myocardial infarction and the impact of troponin determination on clinical practice. Int J Cardiol 2006; 106: 298-306.
38. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pre-treatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-78.
39. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110: 674-78.
40. Ohman EM, Christenson RH, Califf RM, et al. Non-invasive detection of reperfusion after thrombolysis based on serum creatine- kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction. Am Heart J 1993; 126: 819-26.
41. Tanasijevic MJ, Cannon CP, Antman EM, et al. Myoglobin, Creatine-kinase-MB and cardiac troponin I 60-minutes ratios predict infarct related artery patency after thrombolysis for acute myocardial infarction: results from the thrombolysis in myocardial infarction study (TIMI) 10B. J Am Coll Cardiol 1999; 34: 739-47.
42. French JK, Ramanathan K, Stewart JT, Gao W, Thèroux P. White HD: a score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction. Am Heart J 2003; 145: 508-514.
43. Di Serio F, Antonelli G, Trerotoli P, Tampoia M, Matarrese M, Pansini M. Appropriateness of point-of care testing (POCT) in an emergency department. Clin Chim Acta 2003; 333: 185-89.
44. Di Serio F, Amodio G, Varraso L, et al. Integration between point- of care cardiac markers in an emergency/cardiology department and the central laboratory: methodological and preliminary clinical evaluation. Clin Chem Lab 2005; 43: 202-209.
45. McCord J, Nowak RM, McCullough PA, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001; 104: 1483-8.
46. Clerico A, Emdin M. Natriuretic peptides. The hormones of the heart. Milan: Springer Verlag 2006.
47. Clerico A, Emdin M.: Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50: 33-50.
48. Apple FS, Panteghini M, Ravkilde J. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005; 51: 486-93.
49. Emdin M, Clerico A, Clemenza F, et al. Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J Suppl 2005; 6: 308-25.
50. Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008; 101(3A): 29-38.
51. Moe GW, Howlett J, Januzzi JL, Zowall H. Canadian Multicenter Improved Management of Patients With Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-B-type na-triuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115: 3103-10.
52. Miller VM, Redfield MM, McConnell JP. Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis vs risk. Curr Vasc Pharmacol 2007; 5: 15-25.
53. Galvani M, Ottani F, Oltrona L, et al. Italian Working Group on Atherosclerosis, Thrombosis, and Vascular Biology and the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO). N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004; 110: 128-34.
54. Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 2004; 6: 327-33.
55. Weber M, Bazzino O, Navarro E, et al. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission. J Am Coll Cardiol 2008; 51: 1188-95.
56. Throughton RW, Richards M. B-type natriuretic peptides: application for heart failure management in 2005. Int Med J 2005; 35: 377-79.
57. Kirk V, Bay M, Parner J, Krogsgaard K, Herzog TM, Boesgaard S. N terminal proBNP and mortality in hospitalized patients with heart failure and preserved vs reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Failure 2004; 6: 335-41.
58. Throughton RW, Frampto CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentration. Lancet 2000; 355: 1126-30.
59. Apple FS, Wu AH, Mair J, et al. Committee on standardization of markers of cardiac damage of the IFCC.Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51: 810-24.
60. Morrow DA, Sabatine MS, Brennan ML, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J 2008; 29: 1096-102.
61. Miedema MD, Conover CA, MacDonald H, et al. Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy. Am J Cardiol 2008; 101: 35-9.